查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929556

鸡球球虫疫苗市场（按疫苗类型、配方、给药途径、最终用户和分销管道划分），全球预测（2026-2032年）

Coccidiosis Vaccines in Chickens Market by Vaccine Type, Formulation, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年鸡球球虫疫苗市值为2.3737亿美元，预计2026年将成长至2.6183亿美元，到2032年将达到3.7512亿美元，复合年增长率为6.75%。

主要市场统计数据
基准年 2025 2.3737亿美元
预计年份：2026年 2.6183亿美元
预测年份：2032年 3.7512亿美元
复合年增长率 (%) 6.75%

球虫疫苗接种挑战与科学进展的背景架构：推动计画实施和产业合作的因素

球虫仍然是影响全球家禽生产的最重要感染疾病之一，持续受到兽医、养殖户和疫苗研发人员的关注。此病复杂的生命週期以及感染鸡的艾美耳球虫种类繁多，为预防和控制带来了挑战，疫苗与生物安全和控制措施共同发挥关键作用。近年来，免疫学和分子生物学的科学进步拓展了疫苗设计人员可用的技术工具，使得更有针对性的抗原选择和更适合现代生产系统的创新剂型成为可能。

探索科学、监管和现场操作方面相互整合的变革，这些变革将改变疫苗的研发、供应和部署策略。

球虫疫苗领域正经历一系列变革性的转变，这些转变远非简单的产品改进所能比拟。在基因工程和抗原发现领域的突破性进展，拓展了疫苗研发人员可选择的疫苗类型。重组蛋白平台和DNA技术等手段，优化了疫苗的免疫抗原性原性，并开发出针对多种艾美球虫的多价製剂。同时，减毒活疫苗株的改良，包括筛选精准的早熟突变株和非早熟突变株，在广谱保护和成熟的临床应用方面，持续展现出显着的实用优势。

评估2025年美国关税政策变化对采购优先事项、製造地区域化和商业采购趋势的影响

2025年，美国实施的关税和贸易调整措施对全球兽用生技药品供应链以及球虫疫苗的商业性动态产生了连锁反应。某些原料和生技药品成分的进口关税提高，增加了依赖国际供应商的製造商的成本，促使他们重新评估筹资策略并定期与供应商重新谈判。在某些情况下，由于製造商需要在更高的国内生产成本和更短供应链带来的稳定性之间权衡利弊，这导致他们加快了关键投入品本地化的步伐。

对疫苗的剂型、配方选择、给药途径、分销管道和最终用户特征进行详细的細項分析，并结合商业性和技术方面的影响进行探讨。

详细的市场区隔分析揭示了影响产品开发和上市优先顺序的显着差异。根据疫苗类型，研发人员和客户会评估DNA疫苗、减毒活病毒疫苗、重组疫苗和次单位疫苗，每种疫苗的性能和操作方面各不相同。减毒活病毒疫苗因其已确立的现场保护作用而仍然十分重要，并且根据非早熟株和早熟株的选择而进一步区分。每种毒株在安全性、免疫抗原性和生产效率方面各有重点。这些差异也促使人们在製剂策略上做出相对应的选择。市场正在考虑单价疫苗和多价疫苗。单价疫苗可以针对特定的艾美球虫属物种进行标靶标靶化，而多价疫苗在多种寄生虫共存的环境中具有实际优势，可以减少给药频率。

区域比较分析：美洲、欧洲、中东和非洲以及亚太地区的市场特征会影响产品优先顺序、监管方式和分销模式。

区域趋势对疫苗研发重点、监管管道和商业模式有着深远的影响。在美洲，法规环境和垂直整合的生产体系优先考虑快速商业化部署以及针对大规模肉鸡和蛋鸡养殖场量身定制的解决方案，从而导致对高度可控的交付模式和经实践验证的田间性能的强劲需求。同时，欧洲、中东和非洲的管理体制各不相同，生产规模也差异很大。在一些国家，严格的监管监控和高标准的动物福利强调完善的安全记录和可追溯的供应链。而在其他市场，物流限制和小规模农户的存在则推动了对安全可靠、易于接种疫苗的产品的需求。

竞争行为和策略定位展现了开发商、製造商和分销管道如何将科学创新与生产规模和市场进入相结合。

球虫疫苗生态系统中的关键参与企业正采取不同的策略方针，这反映了他们各自的技术组合、製造地和分销管道。为了维持现有方法的优势，一些公司专注于对减毒活病毒疫苗平台进行迭代改进，投资于菌株选择、生产规模扩大和现场检验。同时，优先发展重组疫苗和次单位疫苗等下一代疫苗的公司正在推进抗原优化和佐剂系统的研究，以增强保护性免疫反应并降低反应原性。此外，各公司也致力于递送创新和製剂科学，透过提高口服稳定性、提供即用型饲料和饮用水添加剂以及简化的递送系统来减少农场劳动力，从而实现差异化竞争优势。

製造商、经销商和生产商可采取切实可行的策略重点，以加速采用、增强供应链韧性并展现营运价值。

产业领导者可以采取多项切实可行的措施，将洞察转化为竞争优势，并同时改善牲畜健康。首先，使产品开发蓝图与农场实际运作相符，可确保更快采用新的配方、给药方法和给药方案。早期和迭代式的田间试验，包括在商业农场和小规模农场环境中进行的试验，有助于检验产品的实际性能并发现实施过程中的困难。其次，实现采购多元化并投资于区域製造伙伴关係，可以降低受贸易政策波动的影响，提高前置作业时间的可靠性；同时，与契约製造製造商签订有针对性的产能协议，可以在无需大量固定投资的情况下扩大产能。第三，深化与分销和兽医通路的合作，提供培训、技术支援和综合服务，应能展现整体成本和工作量优势，并增强客户忠诚度。

本执行摘要采用多方面的调查方法，结合专家访谈、文献综合以及贸易和监​​管分析，以确保得出可靠且检验的研究结果。

本执行摘要的研究整合了质性访谈、文献综述和结构化专家咨询，以确保研究结果的平衡性和检验。关键资讯来源包括与兽医、生产经理、疫苗研发人员和分销专家的对话，以了解营运实践和决策标准。这些定性资讯辅以对同行评审文献、监管文件和技术白皮书的系统性回顾，这些文献涉及疫苗免疫学、生产技术和给药方法。此外，供应链和贸易政策分析利用了海关报告、行业公告和公共文件，以识别影响采购和生产策略的结构性变化。

对策略性要务和生态系统环境进行简明扼要、全面深入的分析，阐明哪些疫苗创新能够获得广泛的实际应用。

总而言之，球虫疫苗市场正经历融合变革时期，科学进步、营运需求和政策转变共同决定商业性机会和风险。疫苗剂型日益多样化，减毒减毒活病毒疫苗、重组疫苗、DNA疫苗和次单位疫苗各自提供不同的价值提案，必须满足农场实际情况和法规环境的要求。製剂和给药途径（单价或多价、注射或口服、饲料或水剂）的选择对疫苗的推广应用至关重要，尤其是在生产者寻求优化劳动力、成本和动物福利方面。同时，分销通路策略和终端用户细分也凸显了差异化商业模式的必要性，这些模式能够有效满足小规模生产者和大型生产者的需求。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 鸡球球虫疫苗市场（依疫苗类型划分）

  • DNA疫苗
  • 减毒活病毒疫苗
    • 非早熟菌株
    • 早熟菌株
  • 重组疫苗
  • 次单位疫苗

9. 鸡球球虫疫苗市场（依剂型划分）

  • 单价疫苗
  • 多价疫苗

10. 鸡球虫疫苗市场（依给药途径划分）

  • 注射
    • 肌肉内注射
    • 皮下注射
  • 口服
    • 饲料添加
    • 口服

第十一章 鸡球球虫疫苗市场（以最终用户划分）

  • 家禽
    • 爱好农场
    • 小规模农户
  • 商业家禽养殖场
    • 肉鸡养殖场
    • 蛋鸡养殖场

12. 鸡球球虫疫苗市场依分销管道划分

  • 政府和私人组织
  • 线上发行
  • 零售药房
  • 兽医医院和诊所

13. 各地区鸡球球虫疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 鸡球球虫疫苗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国鸡球球虫疫苗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国鸡球球虫疫苗市场

17. 中国鸡球球虫疫苗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Animalcare Group plc
  • BIMeda, Inc.
  • Biovet JSC
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Elanco Animal Health Incorporated
  • Indian Immunologicals Limited
  • Intervet International BV
  • Laboratorios Hipra, SA
  • Lohmann Animal Health International GmbH
  • Merck & Co., Inc.
  • MSD Animal Health UK Limited
  • Pharmaq AS
  • Phibro Animal Health Corporation
  • Vaxxinova International GmbH
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-0A3806951817

The Coccidiosis Vaccines in Chickens Market was valued at USD 237.37 million in 2025 and is projected to grow to USD 261.83 million in 2026, with a CAGR of 6.75%, reaching USD 375.12 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 237.37 million
Estimated Year [2026] USD 261.83 million
Forecast Year [2032] USD 375.12 million
CAGR (%) 6.75%

Contextual framing of coccidiosis vaccination challenges and scientific progress driving program adoption and industry alignment

Coccidiosis remains one of the most consequential infectious diseases affecting poultry production worldwide, prompting sustained interest from veterinarians, producers, and vaccine developers. The disease's complex life cycle and the diversity of Eimeria species that infect chickens create challenges for prevention and control, and vaccines play a pivotal role alongside biosecurity and management practices. In recent years, scientific progress across immunology and molecular biology has expanded the technical toolkit available to vaccine designers, enabling more targeted antigen selection and innovative delivery formats that better align with modern production systems.

At the same time, global supply chain realignments, evolving regulatory expectations, and growing attention to antimicrobial stewardship have elevated the strategic importance of vaccination programs. Producers increasingly view vaccines not just as disease protectants but as enablers of flock performance, welfare, and downstream product consistency. Consequently, commercial decisions now balance biological efficacy, ease of administration, and logistical fit within vertically integrated production and distribution networks. This introduction sets the stage for more detailed analysis by outlining the interplay between science, commercial imperatives, and operational realities that shape adoption and product development in the coccidiosis vaccine landscape.

Exploration of the converging scientific, regulatory, and on-farm operational shifts transforming vaccine development, delivery, and adoption strategies

The landscape for coccidiosis vaccines is being reshaped by several transformative shifts that extend beyond incremental product improvements. Breakthroughs in genetic engineering and antigen discovery have broadened the palette of vaccine modalities available to developers, with technologies such as recombinant protein platforms and DNA approaches enabling refined immunogenic profiles and the possibility of multivalent formulations targeted at multiple Eimeria species. Meanwhile, the refinement of live attenuated strains, including precise selection of precocious and non-precocious variants, continues to deliver practical benefits in terms of protective breadth and established field performance.

Concurrently, changes in poultry production practices and heightened consumer scrutiny have influenced deployment choices; producers are favoring solutions that minimize labor inputs and support antibiotic stewardship goals. This has accelerated interest in oral delivery options that integrate easily into feeding or water systems, and in polyvalent formulations that reduce handling frequency. Additionally, regulatory authorities are placing greater emphasis on manufacturing consistency and traceability, prompting manufacturers to invest in quality systems and supply chain transparency. Taken together, these technological, operational, and regulatory shifts are fostering an environment where innovation must be matched by pragmatic consideration of administration routes, farm workflows, and stakeholder expectations.

Assessment of how recent tariff shifts in the United States have reshaped sourcing priorities, manufacturing localization, and commercial procurement dynamics in 2025

In 2025, tariff measures and trade policy adjustments enacted by the United States have created a cascade of effects for global veterinary biologics supply chains and the commercial dynamics surrounding coccidiosis vaccines. Elevated import duties on select raw materials and biologics components have increased the cost base for manufacturers that rely on international suppliers, prompting reassessments of sourcing strategies and periodic renegotiations with suppliers. In some cases, the tariff environment has accelerated localization efforts for critical inputs, as manufacturers weigh the trade-offs between higher domestic production costs and the stability afforded by shorter supply chains.

These policy shifts have also influenced procurement decisions among distributors and end users. Where cross-border sourcing had previously delivered cost advantages, buyers are now more likely to prioritize supplier resilience and delivery reliability. As a result, strategic relationships with regional manufacturers and contract manufacturing organizations have become more prominent, and companies are investing in inventory planning and demand signal sharing to mitigate exposure to tariff-driven price volatility. At the commercial interface, sales teams and channel partners are adjusting pricing strategies and contracting terms to reflect evolving landed costs while communicating value through efficacy, ease of use, and total cost of ownership rather than unit price alone. Over the medium term, the industry response to tariffs is encouraging a more diversified, regionally balanced manufacturing footprint and a closer alignment between procurement practices and regulatory compliance.

In-depth segmentation analysis linking vaccine modalities, formulation choices, administration routes, distribution channels, and end-user profiles to commercial and technical implications

A granular view of segmentation reveals meaningful distinctions that influence product development and go-to-market priorities. Based on vaccine type, developers and customers evaluate DNA vaccines, live attenuated vaccines, recombinant vaccines, and subunit vaccines through different performance and operational lenses. Live attenuated products remain prominent for their established field protection and are further differentiated by the selection of non-precocious strains versus precocious strains, each offering distinct balances of safety, immunogenicity, and production efficiency. These modality differences drive parallel choices in formulation strategy, where the market is studied across monovalent vaccines and polyvalent vaccines; monovalent options allow focused targeting of specific Eimeria species, whereas polyvalent vaccines offer practical benefits in multi-species exposure environments and can reduce administration frequency.

Route of administration is another critical axis, with options including injection and oral delivery dictating on-farm compatibility. The injection pathway subdivides into intramuscular and subcutaneous approaches, which tend to be chosen where precise dosing and systemic responses are prioritized, while oral administration routes such as in-feed and via water are preferred for large-scale flocks because they support rapid deployment and lower labor intensity. Distribution channel dynamics also shape access and adoption, spanning government and private organizations, online distribution platforms, retail pharmacies, and veterinary hospitals and clinics; each channel offers different degrees of reach, technical support, and batch handling capabilities. Finally, end-user segmentation captures structural differences in demand and purchasing behavior across backyard flocks and commercial poultry farms. Backyard flocks, which include hobby farms and smallholder farms, often prioritize ease of use and cost-effectiveness, while commercial poultry farms, encompassing broiler farms and layer farms, emphasize scalability, integration with production schedules, and corroborated performance data. Understanding how these segmentation dimensions intersect enables product teams and commercial leaders to tailor formulations, delivery formats, and channel strategies to discrete customer needs and operational constraints.

Comparative regional analysis describing how Americas, Europe Middle East & Africa, and Asia-Pacific market attributes shape product priorities, regulatory approaches, and distribution

Regional dynamics exert a profound influence on vaccine development priorities, regulatory pathways, and commercial models. In the Americas, regulatory ecosystems and vertically integrated production systems often prioritize rapid commercial rollout and solutions that align with large-scale broiler and layer operations, leading to strong demand for administratively efficient delivery formats and validated field performance. Meanwhile, Europe, Middle East & Africa present heterogeneous regulatory regimes and a wide range of production scales; in some countries, intensive regulatory scrutiny and high animal welfare expectations favor well-documented safety profiles and traceable supply chains, while in other markets logistical constraints and smallholder presence drive demand for robust, easy-to-administer products.

Across the Asia-Pacific region, diverse production models and fast-evolving industrialization trends create dynamic market conditions. High-density poultry production centers emphasize solutions that can be deployed at scale and integrated with automated feeding and water systems, while significant smallholder populations in other parts of the region maintain demand for cost-effective, straightforward vaccination approaches. In addition, regional manufacturing capacity and trade relationships shape availability and lead times, with several jurisdictions investing in domestic biologics capabilities to reduce dependence on distant suppliers. These regional characteristics influence not only which product attributes are prioritized but also how manufacturers structure their regulatory strategies, distribution agreements, and stakeholder engagement programs.

Competitive behaviors and strategic positioning that reveal how developers, manufacturers, and channels align scientific innovation with manufacturing scale and market access

Key players in the coccidiosis vaccine ecosystem pursue varied strategic approaches that reflect their technological portfolios, manufacturing footprints, and commercial channels. Some companies emphasize iterative improvement of live attenuated platforms, investing in strain selection, production scaling, and field efficacy validation to preserve the advantages of established approaches. Others prioritize next-generation modalities such as recombinant and subunit vaccines, directing research into antigen optimization and adjuvant systems that enhance protective responses while reducing reactogenicity. A parallel set of firms focus on delivery innovations and formulation science, seeking to differentiate through oral stability, ready-to-use feed or water integrations, and user-friendly dosing systems that lower on-farm labor requirements.

Across the competitive landscape, strategic partnerships and licensing arrangements are common mechanisms to combine scientific strengths with regional commercial capability. Contract manufacturing and fill-finish collaborators play an increasingly important role in enabling rapid capacity expansion, while specialized distributors and veterinary service providers bridge technical support gaps for end users. In addition, several organizations are strengthening quality management systems and regulatory affairs capabilities to expedite approvals and maintain supply continuity under complex cross-border compliance regimes. Collectively, these company-level approaches reflect a broader trend toward aligning technological innovation with pragmatic deployment considerations and channel strategies.

Actionable strategic priorities for manufacturers, distributors, and producers to accelerate adoption, strengthen supply resilience, and demonstrate operational value

Industry leaders can take several practical steps to convert insight into competitive advantage while improving flock health outcomes. First, aligning product development roadmaps with operational realities on farms will ensure that new formulations, delivery methods, and dosing regimens are adopted more rapidly; early and iterative field trials that include both commercial farms and smallholder contexts help validate real-world performance and uncover deployment friction. Second, investing in diversified sourcing and regional manufacturing partnerships will reduce exposure to trade policy volatility and improve lead-time reliability, while targeted capacity agreements with contract manufacturers can provide surge capacity without heavy fixed investments. Third, companies should deepen engagement with distribution and veterinary channels to provide training, technical support, and bundled services that demonstrate total cost and labor advantages, thereby strengthening customer loyalty.

Moreover, firms should prioritize regulatory readiness and transparent data exchange, including standardized safety and efficacy dossiers that accommodate differing regional requirements. Integrating digital tools for traceability, cold-chain monitoring, and usage analytics can also enhance trust among purchasers and regulators. Finally, adopting flexible commercial models-including tiered pricing, value-based contracting, and subscription services for recurring intelligence-can align commercial incentives with customer outcomes and support broader adoption of vaccination programs.

Description of the multi-method research approach combining expert interviews, literature synthesis, and trade and regulatory analysis to ensure robust and validated insights

The research underpinning this executive summary synthesizes primary qualitative interviews, secondary literature review, and structured expert consultations to ensure balanced and verifiable insights. Primary inputs included conversations with veterinarians, production managers, vaccine developers, and distribution specialists to capture operational realities and decision criteria. These qualitative inputs were complemented by a systematic review of peer-reviewed literature, regulatory filings, and technical white papers relevant to vaccine immunology, manufacturing technologies, and administration methodologies. In addition, supply chain and trade policy analyses drew on customs reporting, industry announcements, and public policy documents to identify structural shifts affecting procurement and manufacturing strategies.

Throughout the research process, methodological rigor was maintained by triangulating findings across multiple sources and by subjecting preliminary conclusions to validation with independent experts in avian health and biologics manufacturing. Where applicable, comparative case examples were used to illustrate technology adoption trajectories and regulatory interactions, and limitations were explicitly noted when evidence was heterogeneous. This multi-method approach supports the practical recommendations and segmentation insights provided here, while acknowledging the dynamic nature of the field and the importance of ongoing intelligence gathering.

Concise synthesis of strategic imperatives and ecosystem conditions that will determine which vaccine innovations successfully translate into widespread field adoption

In summary, the coccidiosis vaccine landscape is at a point of convergent change where scientific advances, operational demands, and policy shifts together define commercial opportunities and risks. Vaccine modalities are diversifying, with live attenuated, recombinant, DNA, and subunit approaches each offering distinct value propositions that must be matched to farm-level realities and regulatory contexts. Formulation and administration choices-whether monovalent or polyvalent, injectable or oral, in-feed or via water-play a decisive role in adoption, especially as producers seek to optimize labor, costs, and animal welfare outcomes. Simultaneously, distribution channel strategies and end-user segmentation underscore the need for differentiated commercial models that serve both backyard and commercial producers effectively.

Finally, external pressures such as trade policy adjustments and supply chain disruptions are accelerating regionalization of manufacturing and the importance of resilient sourcing strategies. Companies that integrate scientific innovation with practical deployment planning, regulatory foresight, and strong channel partnerships will be well positioned to deliver value and scale solutions that materially reduce disease burden and support sustainable production practices. Continued monitoring of technological progress, regulatory changes, and on-farm experiences will be essential for stakeholders seeking to convert research into measurable health and performance improvements.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coccidiosis Vaccines in Chickens Market, by Vaccine Type

  • 8.1. DNA Vaccines
  • 8.2. Live Attenuated Vaccines
    • 8.2.1. Non-Precocious Strains
    • 8.2.2. Precocious Strains
  • 8.3. Recombinant Vaccines
  • 8.4. Subunit Vaccines

9. Coccidiosis Vaccines in Chickens Market, by Formulation

  • 9.1. Monovalent Vaccines
  • 9.2. Polyvalent Vaccines

10. Coccidiosis Vaccines in Chickens Market, by Route Of Administration

  • 10.1. Injection
    • 10.1.1. Intramuscular
    • 10.1.2. Subcutaneous
  • 10.2. Oral
    • 10.2.1. In-Feed
    • 10.2.2. Via Water

11. Coccidiosis Vaccines in Chickens Market, by End User

  • 11.1. Backyard Flocks
    • 11.1.1. Hobby Farms
    • 11.1.2. Smallholder Farms
  • 11.2. Commercial Poultry Farms
    • 11.2.1. Broiler Farms
    • 11.2.2. Layer Farms

12. Coccidiosis Vaccines in Chickens Market, by Distribution Channel

  • 12.1. Government & Private Organizations
  • 12.2. Online Distribution
  • 12.3. Retail Pharmacies
  • 12.4. Veterinary Hospitals & Clinics

13. Coccidiosis Vaccines in Chickens Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Coccidiosis Vaccines in Chickens Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Coccidiosis Vaccines in Chickens Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Coccidiosis Vaccines in Chickens Market

17. China Coccidiosis Vaccines in Chickens Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Animalcare Group plc
  • 18.6. BIMeda, Inc.
  • 18.7. Biovet JSC
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Ceva Sante Animale S.A.
  • 18.10. Elanco Animal Health Incorporated
  • 18.11. Indian Immunologicals Limited
  • 18.12. Intervet International B.V.
  • 18.13. Laboratorios Hipra, S.A.
  • 18.14. Lohmann Animal Health International GmbH
  • 18.15. Merck & Co., Inc.
  • 18.16. MSD Animal Health UK Limited
  • 18.17. Pharmaq AS
  • 18.18. Phibro Animal Health Corporation
  • 18.19. Vaxxinova International GmbH
  • 18.20. Vetoquinol S.A.
  • 18.21. Virbac S.A.
  • 18.22. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY NON-PRECOCIOUS STRAINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY NON-PRECOCIOUS STRAINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY NON-PRECOCIOUS STRAINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY PRECOCIOUS STRAINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY PRECOCIOUS STRAINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY PRECOCIOUS STRAINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY MONOVALENT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY MONOVALENT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY MONOVALENT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY POLYVALENT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY POLYVALENT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY POLYVALENT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY IN-FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY IN-FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY IN-FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VIA WATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VIA WATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VIA WATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY HOBBY FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY HOBBY FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY HOBBY FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY SMALLHOLDER FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY SMALLHOLDER FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY SMALLHOLDER FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BROILER FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BROILER FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BROILER FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LAYER FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LAYER FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LAYER FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY GOVERNMENT & PRIVATE ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY GOVERNMENT & PRIVATE ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY GOVERNMENT & PRIVATE ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ONLINE DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ONLINE DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ONLINE DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GCC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 188. GCC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 189. GCC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. GCC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 191. GCC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 192. GCC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. G7 COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 221. G7 COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 222. G7 COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. G7 COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 224. G7 COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 225. G7 COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. NATO COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 232. NATO COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 233. NATO COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. NATO COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 235. NATO COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 236. NATO COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. NATO COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY BACKYARD FLOCKS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY COMMERCIAL POULTRY FARMS, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA COCCIDIOSIS VACCINES IN CHICKENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)